See more : Prodigy Gold NL (PRX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guangzhou Wondfo Biotech Co.,Ltd, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Wialan Technologies, Inc. (WLAN) Income Statement Analysis – Financial Results
- China Dongxiang (Group) Co., Ltd. (3818.HK) Income Statement Analysis – Financial Results
- Aurora Corporation (2373.TW) Income Statement Analysis – Financial Results
- Henderson International Income Trust plc (HINT.L) Income Statement Analysis – Financial Results
- Shun Ho Holdings Limited (0253.HK) Income Statement Analysis – Financial Results
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
About Guangzhou Wondfo Biotech Co.,Ltd
Guangzhou Wondfo Biotech Co.,Ltd, a biological company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious, fertility, and sexually transmitted diseases, as well as immunofluorescence devices to detect cardiovascular diseases, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and other diseases. It also provides blood gas, optical coagulation, and dry chemistry analyzers. The company was founded in 1992 and is headquartered in Guangzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.76B | 5.68B | 3.36B | 2.81B | 2.07B | 1.65B | 1.15B | 547.35M | 428.78M | 365.40M | 247.64M | 227.35M | 183.42M |
| Cost of Revenue | 1.04B | 2.74B | 1.40B | 870.75M | 721.01M | 643.76M | 444.44M | 172.46M | 142.48M | 128.35M | 104.51M | 111.81M | 92.62M |
| Gross Profit | 1.72B | 2.94B | 1.96B | 1.94B | 1.35B | 1.01B | 701.04M | 374.90M | 286.30M | 237.04M | 143.14M | 115.54M | 90.81M |
| Gross Profit Ratio | 62.37% | 51.82% | 58.46% | 69.02% | 65.21% | 60.99% | 61.20% | 68.49% | 66.77% | 64.87% | 57.80% | 50.82% | 49.51% |
| Research & Development | 378.00M | 418.84M | 391.09M | 279.43M | 160.44M | 137.23M | 35.03M | 18.46M | 15.13M | 11.35M | 12.67M | 13.96M | 0.00 |
| General & Administrative | 87.37M | 79.83M | 117.92M | 67.99M | 64.31M | 66.88M | 55.98M | 25.52M | 15.03M | 16.78M | 13.84M | 11.64M | 38.64M |
| Selling & Marketing | 649.99M | 929.61M | 644.31M | 631.13M | 497.51M | 358.34M | 237.94M | 134.40M | 96.51M | 83.84M | 47.58M | 32.68M | 25.64M |
| SG&A | 737.36M | 1.01B | 762.23M | 699.11M | 561.82M | 425.23M | 293.92M | 159.92M | 111.54M | 100.63M | 61.42M | 44.32M | 64.29M |
| Other Expenses | 60.03M | 100.89M | 82.26M | 92.32M | 71.70M | -2.85M | 6.11M | 15.78M | 22.55M | 23.31M | 25.68M | 12.56M | 13.38M |
| Operating Expenses | 1.18B | 1.53B | 1.24B | 1.07B | 793.96M | 615.74M | 413.70M | 238.71M | 171.87M | 146.06M | 97.27M | 78.35M | 65.16M |
| Cost & Expenses | 2.22B | 4.27B | 2.63B | 1.94B | 1.51B | 1.26B | 858.15M | 411.17M | 314.35M | 274.41M | 201.78M | 190.16M | 157.78M |
| Interest Income | 27.61M | 5.15M | 3.02M | 8.57M | 1.94M | 3.71M | 1.97M | 1.11M | 780.47K | 177.52K | 930.96K | 132.29K | 0.00 |
| Interest Expense | 32.20M | 31.06M | 27.76M | 11.14M | 3.83M | 4.67M | 3.81M | 3.40K | 5.79M | 0.00 | 765.56K | 2.27M | 3.07M |
| Depreciation & Amortization | 281.83M | 277.18M | 210.68M | 145.44M | 112.02M | 75.45M | 48.04M | 23.70M | 21.19M | 17.78M | 14.05M | 9.65M | 2.08M |
| EBITDA | 859.13M | 1.67B | 921.22M | 890.71M | 621.01M | 485.76M | 320.52M | 198.30M | 135.61M | 132.34M | 84.94M | 54.88M | 25.64M |
| EBITDA Ratio | 31.07% | 31.21% | 28.20% | 36.12% | 32.12% | 29.75% | 28.61% | 36.80% | 32.41% | 36.92% | 34.76% | 25.83% | 13.72% |
| Operating Income | 549.14M | 1.37B | 691.90M | 740.09M | 508.78M | 411.99M | 260.60M | 158.72M | 121.79M | 91.49M | 44.02M | 29.87M | 23.08M |
| Operating Income Ratio | 19.86% | 24.08% | 20.59% | 26.33% | 24.55% | 24.97% | 22.75% | 29.00% | 28.40% | 25.04% | 17.78% | 13.14% | 12.58% |
| Total Other Income/Expenses | -8.38M | -3.21M | -11.41M | -9.16M | -5.67M | -2.85M | 6.02M | 15.51M | 22.36M | 23.07M | 25.68M | 12.56M | 13.36M |
| Income Before Tax | 540.76M | 1.36B | 680.49M | 730.93M | 503.11M | 409.14M | 266.71M | 174.23M | 144.15M | 114.56M | 69.70M | 42.43M | 36.43M |
| Income Before Tax Ratio | 19.56% | 24.02% | 20.25% | 26.00% | 24.28% | 24.80% | 23.28% | 31.83% | 33.62% | 31.35% | 28.15% | 18.66% | 19.86% |
| Income Tax Expense | 53.33M | 174.50M | 47.91M | 114.13M | 76.02M | 62.56M | 41.65M | 28.72M | 18.80M | 16.20M | 10.70M | 4.55M | 4.76M |
| Net Income | 487.62M | 1.20B | 634.43M | 634.17M | 387.46M | 307.74M | 210.70M | 144.99M | 125.35M | 98.36M | 59.00M | 37.91M | 31.67M |
| Net Income Ratio | 17.64% | 21.07% | 18.88% | 22.56% | 18.70% | 18.65% | 18.39% | 26.49% | 29.23% | 26.92% | 23.83% | 16.67% | 17.27% |
| EPS | 1.10 | 2.71 | 1.43 | 1.44 | 0.88 | 0.71 | 0.52 | 0.35 | 0.35 | 0.32 | 0.19 | 0.12 | 0.17 |
| EPS Diluted | 1.10 | 2.71 | 1.43 | 1.44 | 0.88 | 0.71 | 0.51 | 0.35 | 0.35 | 0.32 | 0.19 | 0.12 | 0.17 |
| Weighted Avg Shares Out | 443.30M | 441.69M | 443.66M | 441.58M | 441.55M | 434.86M | 408.81M | 411.84M | 360.36M | 308.93M | 310.22M | 311.24M | 444.95M |
| Weighted Avg Shares Out (Dil) | 443.30M | 441.69M | 443.66M | 441.58M | 441.55M | 434.86M | 415.01M | 413.74M | 362.13M | 308.96M | 310.27M | 311.25M | 444.95M |
Source: https://incomestatements.info
Category: Stock Reports